248 related articles for article (PubMed ID: 23666316)
21. Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage.
Gallo G; Brock F; Kerkmann U; Kola B; Huizinga TW
RMD Open; 2016; 2(1):e000186. PubMed ID: 27175292
[TBL] [Abstract][Full Text] [Related]
22. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
24. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
Keystone E; Freundlich B; Schiff M; Li J; Hooper M
J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
[TBL] [Abstract][Full Text] [Related]
25. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
[TBL] [Abstract][Full Text] [Related]
27. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial.
Kim HY; Hsu PN; Barba M; Sulaiman W; Robertson D; Vlahos B; Khandker R; Nab H; Freundlich B; Koenig A
Int J Rheum Dis; 2012 Apr; 15(2):188-96. PubMed ID: 22462423
[TBL] [Abstract][Full Text] [Related]
28. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
Genovese MC; Bathon JM; Martin RW; Fleischmann RM; Tesser JR; Schiff MH; Keystone EC; Wasko MC; Moreland LW; Weaver AL; Markenson J; Cannon GW; Spencer-Green G; Finck BK
Arthritis Rheum; 2002 Jun; 46(6):1443-50. PubMed ID: 12115173
[TBL] [Abstract][Full Text] [Related]
29. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
[TBL] [Abstract][Full Text] [Related]
30. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
Gaubitz M; Göttl KH; Behmer O; Lippe R; Meng T; Löschmann PA
Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
[TBL] [Abstract][Full Text] [Related]
31. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
Shi ZC; Fei HP; Wang ZL
Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
[TBL] [Abstract][Full Text] [Related]
35. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.
Emery P; Horton S; Dumitru RB; Naraghi K; van der Heijde D; Wakefield RJ; Hensor EMA; Buch MH
Ann Rheum Dis; 2020 Apr; 79(4):464-471. PubMed ID: 31996367
[TBL] [Abstract][Full Text] [Related]
36. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
Al-Gareeb AIA; Gorial FI; Mahmood AS
Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
[TBL] [Abstract][Full Text] [Related]
37. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.
Tanaka Y; Yamanaka H; Saito K; Iwata S; Miyagawa I; Seto Y; Momohara S; Nagasawa H; Kameda H; Kaneko Y; Izumi K; Amano K; Takeuchi T
Mod Rheumatol; 2012 Apr; 22(2):186-94. PubMed ID: 21901357
[TBL] [Abstract][Full Text] [Related]
38. Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption.
Laganà B; Picchianti Diamanti A; Ferlito C; Germano V; Migliore A; Cremona A; Argento G; David V; Salemi S; D'Amelio R
Int J Immunopathol Pharmacol; 2009; 22(2):447-54. PubMed ID: 19505397
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A
Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
[TBL] [Abstract][Full Text] [Related]
40. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
van der Heijde D; Klareskog L; Rodriguez-Valverde V; Codreanu C; Bolosiu H; Melo-Gomes J; Tornero-Molina J; Wajdula J; Pedersen R; Fatenejad S;
Arthritis Rheum; 2006 Apr; 54(4):1063-74. PubMed ID: 16572441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]